Cargando…

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that directly depletes eosinophils. Its relative efficacy versus other IL-5-targeted treatments for patients with severe, uncontrolled asthma is not yet fully characterised. We performed a matching-adjusted indirect c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourdin, Arnaud, Husereau, Don, Molinari, Nicolas, Golam, Sarowar, Siddiqui, Mohd Kashif, Lindner, Leandro, Xu, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277255/ https://www.ncbi.nlm.nih.gov/pubmed/30309978 http://dx.doi.org/10.1183/13993003.01393-2018

Ejemplares similares

Matching‐adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
por: FitzGerald, J Mark, et al.
Publicado: (2019)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Two-stage matching-adjusted indirect comparison
por: Remiro-Azócar, Antonio
Publicado: (2022)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Correction: Two-stage matching-adjusted indirect comparison
por: Remiro‑Azócar, Antonio
Publicado: (2022)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma
por: Mathur, Sameer K., et al.
Publicado: (2020)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

Real-life cost-effectiveness of benralizumab in patients with severe asthma
por: Padilla-Galo, A., et al.
Publicado: (2021)

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
por: Bourdin, Arnaud, et al.
Publicado: (2021)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma
por: Cañas, José A., et al.
Publicado: (2021)

Standard patient training versus Vik-Asthme chatbot-guided training: ‘AsthmaTrain’ – a protocol for a randomised controlled trial for patients with asthma
por: Suehs, Carey Meredith, et al.
Publicado: (2023)

Equivalence of entropy balancing and the method of moments for matching‐adjusted indirect comparison
por: Phillippo, David M., et al.
Publicado: (2020)

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma
por: Ferguson, Gary T, et al.
Publicado: (2018)

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
por: Liu, Wanshu, et al.
Publicado: (2019)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma
por: Yamada, Hideyasu, et al.
Publicado: (2021)

Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
por: Chan, Rory, et al.
Publicado: (2023)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
por: Jiang, Tammy, et al.
Publicado: (2023)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
por: Tsurumaki, Hiroaki, et al.
Publicado: (2019)

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab
por: Minami, Daisuke, et al.
Publicado: (2018)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
por: Numata, Takanori, et al.
Publicado: (2020)

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5fr267vci2vpcjs0j29npi1h0